Brickell biotech, inc. (VICL)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

0

-

-

-

0

-

-

-

-

-

-

-

-9,374

-

-8,556

-6,333

-7,840

-9,238

-11,516

-15,580

-16,858

-16,492

-14,051

-19,570

-25,411

-31,238

-36,595

-34,438

-32,425

-22,899

-21,964

2,193

1,655

-7,283

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on marketable securities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair Value Adjustment of Warrants

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of discounts and financing costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

386

590

793

1,003

1,087

1,107

1,117

1,111

1,120

1,135

1,159

1,217

1,318

1,497

1,663

1,812

1,956

2,060

2,213

2,368

2,544

2,455

2,328

2,452

2,329

2,421

2,507

0

0

0

Accretion of discount on short-term investments

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Write-off of abandoned patents

-

-

-

-

-

-

-

673

267

0

0

3

11

374

554

555

547

230

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

0

0

0

-

-

-

-

Net gain on sale of long-term investment

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Write-off of abandoned patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Stock-based compensation

1,551

1,532

1,202

506

1,048

711

661

537

572

756

797

827

908

990

1,172

1,396

1,644

1,902

0

0

0

-

-

-

-

-

-

0

0

-

0

0

0

-

-

-

-

Write-off of abandoned patents and licensed technology

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Compensation expense related to stock options and awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of technology license with common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

775

775

775

775

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred contract costs

-

-

-

-

-

-

-

-

-

4,989

5,962

6,680

6,963

5,428

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivables and other assets

-

-

-

-

-

-

-

-1,596

-1,227

1,973

466

321

-821

-840

-2,033

-809

966

995

892

-23

-668

-412

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Compensation expense related to stock options and awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Receivables and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-106

2,714

11,898

1,923

0

0

0

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-621

-632

1,313

666

1,122

502

557

535

-896

-613

-1,415

-1,300

245

816

1,635

-636

-2,331

-1,951

-2,188

-478

861

-2,216

-792

46

-620

1,834

-51

0

0

0

Employee termination benefits accrual

-

-

-

-

-

-

-

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-5,471

-7,917

-9,724

9,931

6,405

9,712

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

0

0

5,232

-

-1,998

-398

54

250

2,073

445

-83

-150

0

0

-54

0

37

75

167

51

0

-51

-76

99

0

0

0

Deferred rent

-

-

-

-

-

-

-

-

-

223

440

619

731

633

535

464

448

432

415

399

384

368

353

337

322

307

291

277

262

247

233

213

191

169

0

0

0

Net Cash Provided by (Used in) Operating Activities

-37,284

-36,000

-25,554

3,089

3,219

3,967

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-16,132

4,349

-2,938

-3,639

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of long-term investment

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-8,487

-

-8,397

-5,079

-5,786

-6,948

-7,760

-10,297

-10,295

-9,806

-12,610

-18,843

-23,887

-29,798

0

0

0

-

-

-

-

-

-

-

-

Proceeds from the sale of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,750

0

0

0

-

-

-

-

Maturities of marketable securities

24,000

19,500

5,500

-2,719

-7,225

0

11,413

33,741

32,175

31,429

31,453

30,637

32,835

30,652

24,368

21,170

20,456

20,183

17,586

14,141

8,339

10,556

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Capital expenditures

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

0

0

33,217

-

33,628

30,209

26,177

20,050

13,706

18,546

24,751

22,643

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

0

0

0

-

-

-

-

Maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

18,031

20,017

20,714

20,220

0

0

0

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

41,461

34,873

25,484

24,598

0

0

0

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

80

52

69

178

255

244

244

140

72

100

91

92

85

69

86

184

332

423

486

675

646

495

487

313

256

0

0

0

Net cash provided by (used in) investing activities

37,012

32,510

18,505

14,566

10,150

-12

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-20,575

-11,989

-1,728

-5,040

0

0

0

CASH FLOWS FROM FINANCING ACTIVITIES:
Patent and licensed technology expenditures

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

53

82

126

187

269

276

388

414

412

467

412

422

409

409

404

401

406

0

0

0

Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-560

-

-9,501

-9,288

-5,881

11

3,713

-4,607

-16,676

-12,426

-7,248

4,178

17,537

25,142

0

0

0

-

-

-

-

-

-

-

-

Proceeds from the issuance of common stock and warrants, net of offering cost

0

-

-

0

0

-

-

0

0

-

0

0

0

-

0

0

6

-

152

2,826

3,927

3,925

3,777

1,537

488

816

817

541

491

48,933

49,015

48,963

48,983

214

0

0

0

Proceeds from the exercise of warrants

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible promissory notes

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of principal of note payable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of withholding taxes for net settlement of restricted stock units

-

-

-

-

-

-

-

-

-

4

4

6

8

14

13

13

14

23

24

48

46

59

70

112

408

482

522

502

247

253

226

217

204

159

0

0

0

Net cash provided by financing activities

4,121

2,636

1,784

-1,274

-768

-1,287

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

48,789

48,746

48,779

55

0

0

0

NET DECREASE IN CASH AND CASH EQUIVALENTS

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

7,749

-

7,746

-7

-8

-20

128

2,778

3,881

3,866

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

2,338

2,427

16,653

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplement Disclosure of Cash Flow Information:
Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-11,739

-

-3,919

-12,126

-23,090

-18,366

-16,151

-13,240

-6,270

-4,322

-14,339

-20,684

-23,449

4,463

12,082

41,106

44,113

-8,624

0

0

0

Interest paid

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplement Disclosure of Non-Cash Investing and Financing Activities:
Reduction of redeemable convertible preferred stock to redemption value

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants to purchase common stock issued with convertible promissory notes

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock issuance costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative liability issued with convertible promissory notes

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-